Answers are grounded in this paper and cite their sources.
Somatic inactivating variants in the gene CDK12, encoding cyclin-dependent kinase 12, generate fusion-induced neoantigens in prostate cancer. This finding supports the hypothesis that prostate cancers with variant CDK12 will have a response to checkpoint inhibitor drugs.
No takes yet. Share an insight, caveat, or question.
Emmanuel S. Antonarakis (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: